Induction of apoptosis in ovarian carcinoma cell line by glucocorticoids, and sex steroid hormones

Kataoka, Akio; Nishida, Takashi; Hirai, Noriyuki; Tomioka, Yoshiki; Sugiyama, Tatsuro; Yakushiji, M

doi:10.3892/or.4.6.1249

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The human ovarian serous adenocarcinoma cell lines SHIN‐3, 12 KOC‐2S, 13 and TU‐OS‐4 14 were provided by the respective establishers. The human ovarian serous adenocarcinoma cell lines OVSAHO and OVKATE were purchased from the Japanese Collection of Research Bioresources (JCRB; Osaka, Japan).…”

Section: Methodsmentioning

confidence: 99%

The role of non‐genomic actions of progesterone and its membrane receptor agonist in ovarian cancer cell death

Koyanagi,

Saga,

Takahashi

et al. 2023

Cancer Reports

View full text Add to dashboard Cite

BackgroundProgesterone therapy is a relatively inexpensive treatment option for endometrial and breast cancers, with few side effects. Two signaling pathways usually mediate the physiological effects of progesterone, namely genomic and non‐genomic actions. Genomic action occurs slowly via the nuclear progesterone receptor (PR), whereas the membrane progesterone receptor (mPR) induces rapid non‐genomic action.AimsWe investigated the effects of progesterone and various PR agonists on ovarian cancer cells.Methods and ResultsPR expression of six serous ovarian cancer cell lines was examined by western blotting, and mPR expression was examined by reverse transcription‐quantitative polymerase chain reaction (RT‐qPCR). PR‐negative and mPR‐positive ovarian cancer cells were exposed to progesterone and seven types of PR agonists (medroxyprogesterone acetate [MPA], dehydroepiandrosterone, dienogest, levonorgestrel, drospirenone, pregnenolone, and allopregnanolone) at 10–400 μM, and viable cell counts after exposure for 30 min were measured using the water‐soluble tetrazolium (WST‐1) assay. Ovarian cancer cell lines were exposed to 100 μM progesterone, and the expression of BAX, a pro‐apoptotic protein, after 1–5 min was examined by western blotting.Western blotting detected no PR expression in the six serous ovarian cancer cell lines. In contrast, RT‐qPCR detected mPR expression in all six serous ovarian cancer cell lines. Progesterone and MPA‐induced cell death in all tested ovarian cancer cell lines in a concentration‐dependent manner, whereas no effect was observed for other PR agonists. Western blotting revealed that pro‐apoptotic protein BAX expression occurred 1 min after exposure to progesterone, suggesting that the cytocidal effects are mediated by rapid non‐genomic action.ConclusionProgesterone and MPA exhibited a rapid cytocidal effect on PR‐negative ovarian cancer cells through non‐genomic action. Progesterone and MPA could be novel adjuvant therapies for ovarian cancer.

show abstract

Section: Methodsmentioning

confidence: 99%

The role of non‐genomic actions of progesterone and its membrane receptor agonist in ovarian cancer cell death

Koyanagi,

Saga,

Takahashi

et al. 2023

Cancer Reports

View full text Add to dashboard Cite

show abstract

“…Human ovarian serous adenocarcinoma cell lines, SHIN‐3 and KOC‐2S, were used in this study as they produce high amounts of VEGF and PDGF, respectively . These cell lines were cultured in DMEM/F12 (Life Technologies, Carlsbad, CA, USA), supplemented with 10% FCS (Sigma‐Aldrich, St. Louis, MO, USA) and 1% penicillin/streptomycin (Life Technologies).…”

Section: Methodsmentioning

confidence: 99%

Vasohibin‐1 expression inhibits advancement of ovarian cancer producing various angiogenic factors

et al. 2016

View full text Add to dashboard Cite

Vasohibin‐1 (VASH1) is a negative feedback regulator of angiogenesis, the first to be discovered, and was identified in vascular endothelial growth factor (VEGF)‐stimulated vascular endothelial cells. Vasohibin‐1 inhibits abnormal vascularization induced by various angiogenic factors including fibroblast growth factor and platelet‐derived growth factor (PDGF), in addition to VEGF. By focusing on this characteristic of VASH1, we investigated the antitumor effects of VASH1 expression on ovarian cancer cells that produce different angiogenic factors. By using a high VEGF‐producing ovarian cancer cell line, SHIN‐3, and a high PDGF‐producing ovarian cancer cell line, KOC‐2S, the cells were transfected with either a VEGF antagonist, soluble VEGF receptor‐1 (sVEGFR‐1, or sFlt‐1), or VASH1 genes to establish their respective cellular expression. The characteristics of these transfectants were compared with controls. We previously reported that the expression of sFlt‐1 inhibited tumor vascularization and growth of high VEGF‐producing ovarian cancer cells, reduced peritoneal dissemination and ascites development, and prolonged the survival time of the host. However, in the current study, the expression of sFlt‐1 had no such effect on the high PDGF‐producing ovarian cancer cells used here, whereas VASH1 expression inhibited tumor vascularization and growth, not only in high VEGF‐producing cells, but also in high PDGF‐producing cells, reduced their peritoneal dissemination and ascites, and prolonged the survival time of the host. These results suggest that VASH1 is an effective treatment for ovarian cancer cells that produce different angiogenic factors.

show abstract

Induction of apoptosis in ovarian carcinoma cell line by glucocorticoids, and sex steroid hormones

Cited by 2 publications

References 0 publications

The role of non‐genomic actions of progesterone and its membrane receptor agonist in ovarian cancer cell death

The role of non‐genomic actions of progesterone and its membrane receptor agonist in ovarian cancer cell death

Vasohibin‐1 expression inhibits advancement of ovarian cancer producing various angiogenic factors

Contact Info

Product

Resources

About